stocks logo

VTVT

vTv Therapeutics Inc
$
15.540
-0.03(-0.193%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
17.000
Open
17.000
VWAP
15.61
Vol
2.18K
Mkt Cap
49.64M
Low
15.520
Amount
34.05K
EV/EBITDA(TTM)
--
Total Shares
2.43M
EV
24.32M
EV/OCF(TTM)
--
P/S(TTM)
5.73K
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Show More
2 Analyst Rating
up Image
128.44% Upside
Wall Street analysts forecast VTVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTVT is 35.50 USD with a low forecast of 35.00 USD and a high forecast of 36.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
up Image
128.44% Upside
Current: 15.540
sliders
Low
35.00
Averages
35.50
High
36.00
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Initiates
$36
2025-04-09
Reason
Alliance Global Partners
James Molloy
Strong Buy
Initiates
$35
2024-12-09
Reason
Alliance Global Partners analyst James Molloy initiated coverage of vTv Therapeutics with a Buy rating and $35 price target. vTv is a clinical-stage pharmaceutical company focused on developing treatment options for metabolic and inflammatory diseases, primarily targeting type 1 diabetes, the analyst tells investors in a research note. The firm says cadisegliatin's mechanism of action allows for liver function restoration.

Valuation Metrics

The current forward P/E ratio for vTv Therapeutics Inc (VTVT.O) is -4.58, compared to its 5-year average forward P/E of -3.21. For a more detailed relative valuation and DCF analysis to assess vTv Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.21
Current PE
-4.58
Overvalued PE
0.26
Undervalued PE
-6.68

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.27
Undervalued EV/EBITDA
-0.76

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
32.69
Current PS
0.00
Overvalued PS
74.65
Undervalued PS
-9.27

Financials

Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+15.57%
-6.50M
Operating Profit
FY2025Q1
YoY :
+3.29%
-6.22M
Net Income after Tax
FY2025Q1
YoY :
-34.19%
-0.77
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
83.8K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

VTVT News & Events

Events Timeline

2025-05-19 (ET)
2025-05-19
09:07:14
vTv Therapeutics appoints Tung as CFO
select
2025-05-15 (ET)
2025-05-15
16:08:13
vTv Therapeutics reports Q1 EPS (77c), consensus (81c)
select
2025-05-15
12:01:50
vTv Therapeutics reports reinitiation of screening in CATT1 Phase 3 trial
select
Sign Up For More Events

News

1.0
06-11Newsfilter
vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series
5.0
05-19Newsfilter
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
4.0
04-09Benzinga
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Sign Up For More News

FAQ

arrow icon

What is vTv Therapeutics Inc (VTVT) stock price today?

The current price of VTVT is 15.54 USD — it has decreased -0.19 % in the last trading day.

arrow icon

What is vTv Therapeutics Inc (VTVT)'s business?

arrow icon

What is the price predicton of VTVT Stock?

arrow icon

What is vTv Therapeutics Inc (VTVT)'s revenue for the last quarter?

arrow icon

What is vTv Therapeutics Inc (VTVT)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for vTv Therapeutics Inc (VTVT)'s fundamentals?

arrow icon

How many employees does vTv Therapeutics Inc (VTVT). have?

arrow icon

What is vTv Therapeutics Inc (VTVT) market cap?